tazarotene has been researched along with calcitriol in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (14.71) | 18.2507 |
| 2000's | 20 (58.82) | 29.6817 |
| 2010's | 7 (20.59) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chandraratna, RA; DiSepio, D; Duvic, M; Ghosn, C; Jacobe, H; Malhotra, M; Nagpal, S; Patel, S; Teng, M | 1 |
| Federman, DG; Froelich, CW; Kirsner, RS | 1 |
| Trozak, DJ | 1 |
| Linden, KG; Weinstein, GD | 1 |
| Cooper, CW | 1 |
| Lebwohl, M; Smith, KC | 1 |
| Hecker, D; Lebwohl, M; Worsley, J; Yueh, G | 1 |
| Guenther, L | 1 |
| Guenther, LC; Pariser, DM; Poulin, YP | 1 |
| Behrens-Williams, SC; Kaskel, P; Kerscher, M; Peter, RU; Pillekamp, H; Schiener, R | 1 |
| Tanghetti, EA | 1 |
| Coynik, D | 1 |
| Altmeyer, P; Hoffmann, M; Stücker, M | 1 |
| Bowman, PH; Koo, JY; Maloney, JE | 1 |
| Guenther, LC | 1 |
| Bruner, CR; Feldman, SR; Fleischer, AB; Ventrapragada, M | 1 |
| Bowen, AR; Herron, MD; Krueger, GG | 1 |
| Del Rosso, J; Friedlander, SF | 1 |
| Koo, J; Lee, E | 1 |
| Chen, YH; Ger, LP; Hsu, NJ; Tzung, TY; Wu, JC | 1 |
| van de Kerkhof, PC | 1 |
| Ceović, R; Husar, K; Kostović, K; Lipozencić, J; Murat-Susić, S; Pasić, A; Skerlev, M | 1 |
| Laffitte, E; Thielen, AM | 1 |
| Tidman, MJ | 1 |
| Dou, W; Hu, J; Sun, J; Zhao, Y | 1 |
| Bangsgaard, N; Rørbye, C; Skov, L | 1 |
| Stein Gold, LF | 1 |
| Bhutani, T; Jeon, C; Koo, K | 1 |
| Kircik, LH; Pariser, DM; Stein Gold, LF | 1 |
| Hansen, JB; Nyholm, N; Patel, DS; Swensen, AR; Veverka, KA; Wu, JJ | 1 |
| Ayyagari, R; Glick, B; Guerin, A; Jacobson, A; Joseph, G; Kircik, L; Lin, T | 1 |
14 review(s) available for tazarotene and calcitriol
| Article | Year |
|---|---|
Topical psoriasis therapy.
Topics: Administration, Cutaneous; Administration, Topical; Anthralin; Anti-Inflammatory Agents; Calcitriol; Coal Tar; Dermatologic Agents; Humans; Keratolytic Agents; Nicotinic Acids; Patient Education as Topic; Psoriasis; Retinoids; Teaching Materials; Vitamin D | 1999 |
Topical corticosteroid therapy in psoriasis vulgaris: update and new strategies.
Topics: Administration, Topical; Anti-Inflammatory Agents; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Glucocorticoids; Humans; Nicotinic Acids; Prednisolone; Psoriasis | 1999 |
Psoriasis: current perspectives with an emphasis on treatment.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Calcitriol; Cyclosporine; Dermatologic Agents; Diagnosis, Differential; Drug Therapy, Combination; Humans; Keratolytic Agents; Methotrexate; Nicotinic Acids; Phototherapy; Psoriasis; PUVA Therapy; Retinoids; Severity of Illness Index; United States | 1999 |
New topicals for mild and moderate psoriasis.
Topics: Administration, Topical; Calcitriol; Dermatologic Agents; Humans; Nicotinic Acids; Psoriasis | 1999 |
Topical antipsoriatics.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Anti-Inflammatory Agents; Calcitriol; Dermatologic Agents; Female; Humans; Male; Nicotinic Acids; Psoriasis; Sensitivity and Specificity | 2000 |
Tazarotene combination treatments in psoriasis.
Topics: Adrenal Cortex Hormones; Calcitriol; Drug Therapy, Combination; Humans; Keratolytic Agents; Nicotinic Acids; Psoriasis; PUVA Therapy; Treatment Outcome | 2000 |
Optimizing treatment with topical tazarotene.
Topics: Acne Vulgaris; Administration, Topical; Adrenal Cortex Hormones; Calcitriol; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Keratolytic Agents; Male; Maximum Tolerated Dose; Nicotinic Acids; Phototherapy; Psoriasis; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2003 |
A systematic review of adverse effects associated with topical treatments for psoriasis.
Topics: Administration, Topical; Adrenal Cortex Hormones; Anthralin; Calcitriol; Coal Tar; Dermatologic Agents; Dihydroxycholecalciferols; Drug Therapy, Combination; Erythema; Humans; Nicotinic Acids; Pain; Pruritus; Psoriasis; Vitamin D | 2003 |
Corticosteroids: options in the era of steroid-sparing therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Calcineurin Inhibitors; Calcitriol; Child; Combined Modality Therapy; Dermatitis, Atopic; Dosage Forms; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Infant; Nicotinic Acids; Psoriasis; Ultraviolet Therapy | 2005 |
Treatment of childhood psoriasis.
Topics: Adrenal Cortex Hormones; Anthralin; Calcitriol; Child; Cyclosporine; Humans; Methotrexate; Nicotinic Acids; Phototherapy; Psoriasis; Retinoids | 2006 |
[Topical treatments for psoriasis in 2009].
Topics: Administration, Cutaneous; Anthralin; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Emollients; Humans; Keratolytic Agents; Nicotinic Acids; Ointments; Psoriasis; PUVA Therapy; Quality of Life; Tacrolimus; Treatment Outcome; Vitamins | 2009 |
Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments.
Topics: Acitretin; Administration, Cutaneous; Adrenal Cortex Hormones; Calcineurin Inhibitors; Calcitriol; Coal Tar; Contraindications; Cyclosporine; Dermatologic Agents; Female; Humans; Immunosuppressive Agents; Methotrexate; Nicotinic Acids; Pregnancy; Pregnancy Complications; Psoriasis; PUVA Therapy; Tumor Necrosis Factor-alpha; Ultraviolet Therapy; Ustekinumab | 2015 |
Topical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence.
Topics: Administration, Cutaneous; Anthralin; Betamethasone; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Humans; Nicotinic Acids; Patient Compliance; Pharmaceutical Vehicles; Practice Guidelines as Topic; Psoriasis; Quality of Life; Severity of Illness Index; Tacrolimus; Treatment Outcome; Vitamin D | 2016 |
Beyond monotherapy: a systematic review on creative strategies in topical therapy of psoriasis.
Topics: Administration, Topical; Calcitriol; Clobetasol; Databases, Factual; Dermatologic Agents; Humans; Nicotinic Acids; Phototherapy; Psoriasis; Tacrolimus | 2017 |
8 trial(s) available for tazarotene and calcitriol
| Article | Year |
|---|---|
A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Calcitriol; Dermatologic Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Gels; Glucocorticoids; Humans; Male; Middle Aged; Mometasone Furoate; Nicotinic Acids; Ointments; Pregnadienediols; Psoriasis; Treatment Outcome | 2000 |
Calcipotriol vs. tazarotene as combination therapy with narrowband ultraviolet B (311 nm): efficacy in patients with severe psoriasis.
Topics: Administration, Topical; Adult; Calcitriol; Combined Modality Therapy; Dermatologic Agents; Female; Humans; Male; Middle Aged; Nicotinic Acids; Psoriasis; Treatment Outcome; Ultraviolet Therapy | 2000 |
An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +/- corticosteroid.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Calcitriol; Child; Cross-Sectional Studies; Dermatologic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Nicotinic Acids; Patient Satisfaction; Psoriasis; Severity of Illness Index; Treatment Outcome | 2000 |
Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment.
Topics: Administration, Topical; Anti-Inflammatory Agents; Calcitriol; Dermatologic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Male; Middle Aged; Nicotinic Acids; Patient Satisfaction; Psoriasis; Severity of Illness Index; Treatment Outcome | 2000 |
Instrumental evaluation of retinoid-induced skin irritation.
Topics: Administration, Cutaneous; Adult; Calcitriol; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Forearm; Humans; Irritants; Male; Mometasone Furoate; Nicotinic Acids; Pregnadienediols; Psoriasis; Reproducibility of Results; Retinoids; Sensitivity and Specificity; Skin; Water Loss, Insensible | 2002 |
Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study.
Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Arm; Calcitriol; Clobetasol; Dermatologic Agents; Drug Synergism; Drug Therapy, Combination; Elbow; Female; Gels; Glucocorticoids; Humans; Leg; Male; Nicotinic Acids; Ointments; Pilot Projects; Prospective Studies; Psoriasis; Severity of Illness Index; Thorax; Treatment Outcome | 2002 |
Seborrheic keratoses: a study comparing the standard cryosurgery with topical calcipotriene, topical tazarotene, and topical imiquimod.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aminoquinolines; Calcitriol; Cryosurgery; Dermatologic Agents; Drug Administration Schedule; Female; Humans; Imiquimod; Keratosis, Seborrheic; Male; Middle Aged; Nicotinic Acids; Pilot Projects; Retinoids; Treatment Outcome | 2004 |
Comparison of tazarotene 0.1% gel plus petrolatum once daily versus calcipotriol 0.005% ointment twice daily in the treatment of plaque psoriasis.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Calcitriol; Child; Dermatologic Agents; Double-Blind Method; Drug Administration Schedule; Female; Gels; Humans; Male; Middle Aged; Nicotinic Acids; Ointments; Petrolatum; Prospective Studies; Psoriasis; Severity of Illness Index; Treatment Outcome | 2005 |
12 other study(ies) available for tazarotene and calcitriol
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Tazarotene-induced gene 2 (TIG2), a novel retinoid-responsive gene in skin.
Topics: Administration, Topical; Amino Acid Sequence; Base Sequence; Calcitriol; Cells, Cultured; Chromosome Mapping; Chromosomes, Human, Pair 17; DNA, Complementary; Gene Expression; Humans; Molecular Sequence Data; Nicotinic Acids; Psoriasis; Receptors, Retinoic Acid; Retinoid X Receptors; RNA, Messenger; Sequence Homology, Nucleic Acid; Skin; Skin Physiological Phenomena; Transcription Factors; Up-Regulation | 1997 |
In vitro compatibility of tazarotene with other topical treatments of psoriasis.
Topics: Administration, Topical; Betamethasone; Calcitriol; Clobetasol; Dermatologic Agents; Drug Evaluation, Preclinical; Drug Incompatibility; Fluocinonide; In Vitro Techniques; Mometasone Furoate; Nicotinic Acids; Pregnadienediols; Psoriasis | 2000 |
Modern modified 'ultra' Goeckerman therapy: a PASI assessment of a very effective therapy for psoriasis resistant to both prebiologic and biologic therapies.
Topics: Acitretin; Anthralin; Calcitriol; Coal Tar; Combined Modality Therapy; Female; Humans; Keratolytic Agents; Male; Methotrexate; Middle Aged; Nicotinic Acids; Phototherapy; Psoriasis; Salicylic Acid; Severity of Illness Index; Time Factors; Ultraviolet Therapy | 2005 |
[Treatment options in monogenic disorders of keratinization].
Topics: Acitretin; Calcitriol; Controlled Clinical Trials as Topic; Dermatologic Agents; Eccrine Glands; Gels; Hamartoma; Humans; Ichthyosis Vulgaris; Ichthyosis, X-Linked; Keratoderma, Palmoplantar; Keratolytic Agents; Keratosis; Nicotinic Acids; Ointments; Porokeratosis; Retinoids; Sweat Gland Diseases; Time Factors; Treatment Outcome | 2003 |
Childhood psoriasis: often favorable outcome.
Topics: Acitretin; Administration, Topical; Anthralin; Calcitriol; Child; Cyclosporine; Dermatologic Agents; Emollients; Etanercept; Humans; Immunoglobulin G; Immunosuppressive Agents; Methotrexate; Nicotinic Acids; Plant Extracts; Psoriasis; Receptors, Tumor Necrosis Factor; Salicylates; Steroids; Tars; Treatment Outcome; Ultraviolet Therapy | 2009 |
Improving outcomes in patients with psoriasis.
Topics: Adrenal Cortex Hormones; Anthralin; Calcineurin Inhibitors; Calcitriol; Dermatologic Agents; Humans; Nicotinic Acids; Psoriasis; Quality of Life; Severity of Illness Index; Tars | 2013 |
A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model.
Topics: Adjuvants, Immunologic; Administration, Topical; Aminoquinolines; Animals; Anti-Inflammatory Agents; Calcitriol; Camptothecin; Clobetasol; Dermatologic Agents; Disease Models, Animal; Humans; Imiquimod; Mice; Mice, Inbred BALB C; Nicotinic Acids; Psoriasis; Topoisomerase I Inhibitors | 2014 |
Understanding topical therapies for psoriasis.
Topics: Administration, Cutaneous; Biological Products; Calcitriol; Dermatologic Agents; Drug Combinations; Drug Therapy, Combination; Glucocorticoids; Humans; Nicotinic Acids; Psoriasis | 2019 |
Reply: Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matchi
Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis | 2020 |
Re: Wu JJ, Hansen JB, Patel DS, et al. Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adju
Topics: Betamethasone; Calcitriol; Clobetasol; Humans; Nicotinic Acids; Psoriasis | 2020 |